PATENT CLAIM ANALYSIS

Application Number: 15771704
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["424", "472000"]

Abstract:
This invention relates to pharmaceutical controlled release compositions of salicylate-releasing actives for the treatment of tau protein-related neurodegenerative diseases and disorders.

Claim (Index 19):
The method of  claim 18 , wherein the neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Amyotrophic lateral sclerosis-Parkinsonism-dementia (ALS/PD) complex of Guam, Argyrophilic grain disease, British type amyloid angiopathy, Corticobasal degeneration, Dementia pugilistica (TBI), Down's syndrome, Frontotemporal dementia, Gerstmann-Straussler-Scheinker, Hallenvorden-Spatz disease, Inclusion body myositis, Multisystem atrophy, Myotonic dystrophy, Niemann-Pick disease type C, Parkinson w/dementia of Guadeloupe, Pick's disease, Presenile dementia with tangles, Prion protein amyloid angiopathy, Progressive supranuclear palsy, Post-encephalitic parkinsonism, Subacute sclerosing panencephalitis, and Tangle only dementia.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.04762
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15543199', '15010212', '10015930', '13186006', '11120139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7828172675175383
- 35 USC 102 Novelty (BERT): 0.4963359137477572
- Combined Prediction Score: 0.7541691321405602
- Mean Citation Score: 237.953648
- Max Citation Score: 264.3504
- Similarity Product: 208.26438760271068

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test